Zusammenfassung
Die Radiotherapie gehört zusammen mit der Chirurgie, Chemotherapie und neuerdings der Immuntherapie zu den elementaren Säulen der Krebstherapie. Zunehmend in den Fokus der modernen Krebstherapie rückt die Lebensqualität der Patienten, die in besonderem Maße von den akuten und späten Normalgewebsreaktionen nach der Tumortherapie abhängt. Aufgrund verbesserter Heilungsraten für Krebs in den vergangenen Jahrzehnten gewinnen dabei besonders die Spätreaktionen der Radiotherapie an Bedeutung. Ein tiefgreifendes Verständnis der radiogenen Normalgewebsreaktionen erlaubt eine suffiziente Diagnose und spezifische Therapie der Nebenwirkungen und damit eine Verbesserung der Lebensqualität der Patienten. In diesem Beitrag werden Normalgewebsreaktionen verschiedener Organsysteme unter Berücksichtigung der Strahlenbiologie behandelt sowie vorhandene und zukünftige Möglichkeiten zur Behandlung von Strahlennebenwirkungen diskutiert.
Abstract
Along with chemotherapy, surgery and immunotherapy, radiotherapy is a mainstay of cancer treatment. Considering the improving survival rates for various malignancies during the past decades, the importance of radiation-induced late normal tissue response is increasing. Quality of life is becoming an important issue in modern cancer treatment and is correlated with acute and late normal tissue response after radiotherapy. A profound understanding of radiation-induced normal tissue response is necessary to sufficiently diagnose and treat radiation-induced side effects and thereby increase the patients’ quality of life. Here, the various normal tissue responses in consideration of the radiation biology are specified and prospective options to attenuate radiation-induced side effects are discussed.
Literatur
Welzel T, Tanner JM (2018) Nebenwirkungen nach Strahlentherapie in der Bildgebung. Radiologe 58. https://doi.org/10.1007/s00117-018-0412-6
Sterzing F et al (2009) Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents—a single institution’s experience and a review of the literature. Radiat Oncol 4:37
Askoxylakis V et al (2016) Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis. Radiat Oncol 11:17
Nutting CM et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136
Hall EJ, Wuu C‑S (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88
Zwicker F et al (2015) In vivo measurement of dose distribution in patients’ lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer. J Radiat Res 56(2):239–247
Nicolay NH et al (2016) High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer: experience from a large single-center cohort. Strahlenther Onkol 192(7):458–466
Roeder F et al (2016) Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases. Radiother Oncol 119(1):22–29
Hoffmann M et al (2015) Long term results of postoperative intensity-modulated radiation therapy (IMRT) in the treatment of squamous cell carcinoma (SCC) located in the oropharynx or oral cavity. Radiat Oncol 10:251
Roeder F et al (2014) Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 9:191
Thieke C et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 10(1):267
Miralbell R et al (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54(3):824–829
Durante M, Debus Heavy Charged Particles J (2018) Does improved precision and higher biological effectiveness translate to better outcome in patients? Semin Radiat Oncol 28(2):160–167
Jensen AD et al (2016) High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years’ experience with raster-scanned carbon ion therapy. Radiother Oncol 118(2):272–280
Jensen AD et al (2015) Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer 121(17):3001–3009
Uhl M et al (2014) Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 120(21):3410–3417
Huber PE et al (2001) Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 59(2):161–167
Emami B et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122
Lawrence YR et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27
Wenz F et al (2000) Prospective evaluation of delayed central nervous system (CNS) toxicity of hyperfractionated total body irradiation (TBI). Int J Radiat Oncol Biol Phys 48(5):1497–1501
Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10(4):322–328
Kirkpatrick JP et al (2011) Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. J Radiosurg SBRT 1(2):95–107
Huber PE et al (2001) Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 49(5):1339–1349
Combs SE et al (2013) Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 106(2):186–191
Combs SE et al (2005) Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 63(1):75–81
Saleh-Ebrahimi L et al (2013) Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer—a retrospective single center analysis. Radiat Oncol 8:20
Henson BS et al (2001) Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 37(1):84–93
Stephens LC et al (1991) Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer 67(6):1539–1543
Wang X, Eisbruch A (2016) IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res 57(Suppl 1):i69–i75
Munter MW et al (2007) Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys 67(3):651–659
Bras J, de Jonge HKT, van Merkesteyn JPR (1990) Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 11(4):244–250
Zwicker F et al (2011) Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. Head Neck 33(12):1695–1702
Coggle JE, Lambert BE, Moores SR (1986) Radiation effects in the lung. Environ Health Perspect 70:261–291
Roeder F et al (2010) Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol 186(3):149–156
Guckenberger M et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8(8):1050–1058
Catane R et al (1979) Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol Biol Phys 5(9):1513–1518
Pearson D et al (1978) The interaction of actinomycin D and radiation. Int J Radiat Oncol Biol Phys 4(1):71–73
Cuzick J et al (1987) Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71(1):15–29
Weberpals J et al (2018) Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy167
Schultz-Hector S, Trott K‑R (2007) Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 67(1):10–18
Halyard MY et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 27(16):2638
Classen J et al (1998) Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol 174:82–84
Dawson LA et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53(4):810–821
Russell AH et al (1993) Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the rtog dose escalating protocol. Int J Radiat Oncol Biol Phys 27(1):117–123
Andratschke N et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283
Pan CC et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3):S94–S100
Dawson LA et al (2010) Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 76(3, Supplement):S108–S115
Cheng JC, Schultheiss TE, Wong JY (2008) Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 71(5):1436–1443
Crew JP, Jephcott CR, Reynard JM (2001) Radiation-induced haemorrhagic cystitis. Eur Urol 40(2):111–123
Nicolay NH et al (2015) Mesenchymal stem cells—a new hope for radiotherapy-induced tissue damage? Cancer Lett 366(2):133–140
Nicolay NH et al (2015) Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic. Oncotarget 6(23):19366–19380
Lalu MM et al (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 7(10):e47559
Chapel A et al (2013) New insights for pelvic radiation disease treatment: multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy. World J Stem Cells 5(4):106–111
Rühle A et al (2018) The radiation resistance of human multipotent mesenchymal stromal cells is independent of their tissue of origin. Int J Radiat Oncol Biol Phys 100(5):1259–1269
Nicolay NH et al (2013) Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys 87(5):1171–1178
Abdollahi A et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201(6):925–935
Flechsig P et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18(13):3616–3627
Dadrich M et al (2016) Combined inhibition of TGFbeta and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology 5(5):e1123366
Bickelhaupt S et al (2017) Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw339
Gorina E et al (2017) PRAISE, a randomized, placebo-controlled, double-blind phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. Eur Respiratory Soc 50:OA3400. https://doi.org/10.1183/1393003.congress-2017.OA3400
Sternlicht MD et al (2018) Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. Respir Res 19(1):14
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Rühle und P. E. Huber geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Rühle, A., Huber, P.E. Normalgewebe: Strahlenempfindlichkeit, Toxizität, Konsequenzen für die Planung. Radiologe 58, 746–753 (2018). https://doi.org/10.1007/s00117-018-0430-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-018-0430-4